“In Vitro Diagnostics (IVD) market set to grow to $91bn by 2024” says new Visiongain report

14 May 2019
Pharma

Visiongain has launched a new pharma report Medical Devices Leader Series : In Vitro Diagnostics (IVD) Companies Market Report : Danaher Corporation, Abbott Laboratories, Bio-Rad Laboratories, Roche, Siemens AG, Sysmex, Other Companies.

The global in vitro diagnostics (IVD) market is estimated to have reached $69.2bn in 2018. In 2018, Visiongain notes that Big Pharma companies, namely Roche, Danaher and Siemens dominated the sector accounting for 42.4% of the global IVD market with combined revenue of $29.3bn.

The lead analyst of the report commented "In recent years, the IVD market has experienced increased consolidation among industry participants, with significant merger and acquisition (M&A) activity, especially among larger companies as they diversify and manoeuvre for stronger positions. This has been done primarily in response to increased competition to maintain or increase market share, and to solidify a company’s position in the market. Small innovative companies are providing new technologies which feed into the development of products by leading players. Such companies represent potential acquisition targets for corporations seeking opportunities."

Leading companies featured in the report include Abbott Laboratories, Becton, Dickinson and Company (BD), Bio-Rad Laboratories, Inc., Danaher Corporation, Laboratory Corporation of America (LabCorp), QIAGEN, Roche, Siemens AG, Sysmex Corporation, Thermo Fisher Scientific and other companies.

Notes for Editors
If you are interested in a more detailed overview of this report, please send an e-mail to sara.peerun@visiongain.com or call her on +44 (0) 20 7549 9987.

About Visiongain
Visiongain is one of the fastest-growing and most innovative independent media companies in Europe. Based in London, UK, Visiongain produces a host of business-to-business reports focusing on the automotive, aviation, chemicals, cyber, defence, energy, food & drink, materials, packaging, pharmaceutical and utilities sectors.

Visiongain publishes reports produced by analysts who are qualified experts in their field. Visiongain has firmly established itself as the first port of call for the business professional who needs independent, high-quality, original material to rely and depend on.

Recent News

Visiongain Publishes Single-Cell Analysis Market Report 2022-2032

The global single cell analysis market was valued at US$3,255.0 million in 2022 and is projected to grow at a CAGR of 15.1% during the forecast period 2022-2032.

26 May 2022

Read

Visiongain Publishes Ophthalmic Devices Market Report 2022-2032

The number of people who are blind or have poor vision is expected to rise considerably in the coming years. The growing elderly population is one of the key drivers of the Ophthalmic Devices Market’s upward trend.

19 April 2022

Read

Visiongain Publishes Vaccine Contract Manufacturing Market Report 2022-2032

The growing global health system has made significant contributions to protecting and promoting human health. However, long-standing, developing, and reemerging infectious disease risks continue to plague the planet

13 April 2022

Read

Visiongain Publishes Pharmaceutical Contract Manufacturing Market Report 2022-2032

The major driving factor contributing towards the growth of pharmaceutical contract manufacturing market are increase in investments in pharmaceutical R&D, rise in number of patent expiry, rising demand of generic drugs, and investment in advanced manufacturing technologies. However, use of serialization can thwart the market growth.

13 April 2022

Read

Kelloggs
3m
Thales
Shell
TEVA
Lockheed-Martin
Pfizer
Raytheon
Halliburton
Du-Pont
Honeywell
Daimler
BASF
Bayer
BP
BAE-Systems
Unilever